tirzepatide surmount 4 SURMOUNT-1 Trial Stopping Tirzepatide Leads to Rebound

Splitting weekly doses into twice-weekly injections may improve tolerability for some, though this is off-label and should be discussed with a healthcare provider

Cell Commun Signal (2013) 11:34

In addition, NNMTi promotes the secretion of antiinflammatory lipids (such as PAHSA) by adipocytes, further relieving adipose inflammation and improving metabolic function

Your provider will help you transition to the appropriate equivalent dose to ensure your weight loss progress remains steady and your side effects are minimized

If symptoms are severe, persistent, or include severe abdominal pain or dehydration, contact your doctor promptly